With similar objectives, Moghe’s group and Gantenbein-Ritter’s group have reported encouraging studies that reveal the effectiveness of multidimensional morphological parameter modeling in the evaluation of stem cell differentiation potentials. However, in spite of the effectiveness of these strategies, such quantitative and bioinformatic technologies are still not fully utilized in clinical cell therapies. To advance imagebased cellular evaluation technologies as a reliable supportive option in regenerative medicine, it will be necessary to perform more studies that connect computational technology with stem cell biology. We believe our morphology-based modeling approach will contribute to new technological developments in regenerative medicine. It has been known that cell shape takes a part in the regulation of biological processes, such as proliferation and differentiation. Although our main focus was to utilize such morphological information as ”a signature of biological reflection” instead of investigating its meaning, our gene expression analysis and LASSO model interpretation have revealed the involvement of previously known cell shape-regulatory AZ 960 proteins, such as RHO-related proteins. Therefore, we believe that our morphology-based modeling approach will contribute not only to the new technological developments in regenerative medicine, but also for deeper understanding of morphology effect in stem cell biology. Stable angina pectoris symptoms with no obstructive coronary artery disease at angiography remain a great challenge for physicians and patients. Not only is this seemingly paradoxical condition frequent in clinical practice, as nearly two thirds of women and one third of men undergoing first-time coronary angiography due to symptoms of SAP are found to have no obstructive CAD, but it is also associated with increased risk of major cardiovascular events, and symptoms persisting for years. However, the previously published ‘time-to-first-event’ analyses do not fully reflect the true burden of disease from symptoms of SAP and no obstructive CAD at angiography which would require taking recurrent events into account. Additionally, previous risk analyses of SAP symptoms with no obstructive CAD at angiography ignore a vast amount of information on the patient’s outcomes such as a broader spectrum of hospital admissions, recatheterizations, and primary care contacts. While the impact of death and major adverse cardiovascular events are obvious, the importance of softer endpoints should not be underestimated. Such events are not only distressing for patients and their families, but they may also very well be a major driver of the economic burden of SAP symptoms with no obstructive CAD at angiography. The aim of the present study was to evaluate the total disease burden in terms of cardiovascular hospitalization, repeated catheterization, LY294002 non-cardiovascular hospitalization and family doctor consultation in patients with SAP symptoms and no obstructive CAD at angiography compared to asymptomatic reference individuals and obstructive CAD patients. Reference individuals and patients with angiographically normal coronary arteries were younger than patients with CAD.